Consideration of Noninvasive Hemodynamic Monitoring to
Target Reduction of Blood Pressure Levels: The CONTROL Trial

High BP develops and perpetuates through abnormal hemodynamics including elevated cardiac output, systemic vascular resistance, and/or fluid volume.

In the CONTROL multicenter trial, hypertensive patients were randomized to a standard-care arm or ICG-care arm that used hemodynamics to individualize antihypertensive treatment.¹ Compared to the standard-care arm over a 3 month period, the ICG-care arm achieved:

• 8/7 mm Hg greater BP reduction
• Greater attainment of goal BP<140/90 mm Hg (77% vs 57%) and aggressive goal BP<130/85 mm Hg (55% vs 27%)
• 44% lower cost for each mm Hg of reduced systolic BP and 71% lower cost for each mm Hg of reduced diastolic BP²

Using ICG to individualize treatment in your hypertensive patients may lead to better and more cost-effective BP control.

Click here for specific reimbursement information.

Click here to request more information on products and clinical studies.

²Ferrario C, Smith R: for the CONTROL Trial Investigators. Cost-Effectiveness of Impedance
Cardiography Testing in Uncontrolled Hypertension. Am Heart Hosp J. 2006;4:279-289.

Free download: Resistant Hypertension Trial

Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic
management to specialist care. Hypertension. 2002;39:982-988.

Sponsored by CardioDynamics - The ICG Company

Home | Products | Clinicians | Patients | Customers | Investors | Company | Contact Us | BioZ Newsletter